Oncotarget

Research Papers:

Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans

Philip Carter _, Costi Alifrangis, Biancastella Cereser, Pramodh Chandrasinghe, Lisa Del Bel Belluz, Nina Moderau, Fotini Poyia, Lee S. Schwartzberg, Neha Tabassum, Jinrui Wen, Jonathan Krell and Justin Stebbing

PDF  |  HTML  |  How to cite  |  Press Release

Oncotarget. 2018; 9:17589-17596. https://doi.org/10.18632/oncotarget.24564

Metrics: PDF 1244 views  |   HTML 2229 views  |   ?  


Abstract

Philip Carter1, Costi Alifrangis2, Biancastella Cereser1, Pramodh Chandrasinghe1,3, Lisa Del Bel Belluz1, Nina Moderau1, Fotini Poyia1, Lee S. Schwartzberg4, Neha Tabassum1, Jinrui Wen1, Jonathan Krell1 and Justin Stebbing1

1Department of Surgery and Cancer, Imperial College, London, UK

2Department of Oncology, University College Hospital, London, UK

3Department of Surgery, University of Kelaniya, Kelaniya, Sri Lanka

4West Cancer Center, The University of Tennessee, Memphis, USA

Correspondence to:

Philip Carter, email: [email protected]

Keywords: tumor profiling; breast cancer; cancer treatment

Received: July 29, 2017     Accepted: October 28, 2017     Epub: February 24, 2018     Published: April 03, 2018

ABSTRACT

We used data obtained by Caris Life Sciences, to evaluate the benefits of tailoring treatments for a breast carcinoma cohort by using tumor molecular profiles to inform decisions. Data for 92 breast cancer patients from the commercial Caris Molecular Intelligence database was retrospectively divided into two groups, so that the first always followed treatment recommendations, whereas in the second group all patients received at least one drug after profiling that was predicted to lack benefit. The biomarker and drug associations were based on tests including fluorescent in situ hybridization and DNA sequencing, although immunohistochemistry was the main test used.

Patients whose drugs matched those recommended according to their tumor profile had an average overall survival of 667 days, compared to 510 days for patients that did not (P=0.0316). In the matched treatment group, 26% of patients were deceased by the last time of monitoring, whereas this was 41% in the unmatched group (P=0.1257). We therefore confirm the ability of tumor molecular profiling to improve survival of breast cancer patients. Immunohistochemistry biomarkers for the androgen, estrogen and progesterone receptors were found to be prognostic for survival.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24564